Neurocrine Biosciences Inc (NBIX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Neurocrine Biosciences Inc stock (NBIX) is currently trading at $131.13. Neurocrine Biosciences Inc PE ratio is 28.08. Neurocrine Biosciences Inc PS ratio (Price-to-Sales) is 4.60. Analyst consensus price target for NBIX is $178.04. WallStSmart rates NBIX as Buy.
- NBIX PE ratio analysis and historical PE chart
- NBIX PS ratio (Price-to-Sales) history and trend
- NBIX intrinsic value — DCF, Graham Number, EPV models
- NBIX stock price prediction 2025 2026 2027 2028 2029 2030
- NBIX fair value vs current price
- NBIX insider transactions and insider buying
- Is NBIX undervalued or overvalued?
- Neurocrine Biosciences Inc financial analysis — revenue, earnings, cash flow
- NBIX Piotroski F-Score and Altman Z-Score
- NBIX analyst price target and Smart Rating
Neurocrine Biosciences Inc
📊 No data available
Try selecting a different time range
NBIX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Neurocrine Biosciences Inc (NBIX)
NBIX trades at a significant discount to its Graham intrinsic value of $218.56, offering a 37% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Neurocrine Biosciences Inc (NBIX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, operating margin. Overall metrics suggest strong investment potential with favorable risk/reward.
Neurocrine Biosciences Inc (NBIX) Key Strengths (8)
Growing significantly faster than its price suggests
Earnings per share surging 47.70% year-over-year
101.69% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $28 kept per $100 revenue
Strong revenue growth at 28.30% annually
Strong profitability: $17 kept per $100 revenue
Solid profitability: $16 profit per $100 equity
Supporting Valuation Data
Neurocrine Biosciences Inc (NBIX) Areas to Watch (2)
Premium valuation at 4.6x annual revenue
Premium pricing at 3.9x book value
Supporting Valuation Data
Neurocrine Biosciences Inc (NBIX) Detailed Analysis Report
Overall Assessment
This company scores 75/100 in our Smart Analysis, earning a B+ grade. Out of 10 metrics analyzed, 8 register as strengths (avg 8.8/10) while 2 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, EPS Growth, Institutional Own.. Valuation metrics including PEG Ratio (0.27) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 16.40%, Operating Margin at 28.20%, Profit Margin at 16.70%. Growth metrics are encouraging with Revenue Growth at 28.30%, EPS Growth at 47.70%.
The Bear Case
The primary concerns are Price/Sales, Price/Book. Some valuation metrics including Price/Sales (4.60), Price/Book (3.94) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 16.40% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 28.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of PEG Ratio and EPS Growth makes a compelling case at current levels. The key risk is Price/Sales, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B+ grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NBIX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NBIX's Price-to-Sales ratio of 4.60x trades at a deep discount to its historical average of 246.71x (3th percentile). The current valuation is 100% below its historical high of 1981.47x set in Nov 2015, and 3% above its historical low of 4.48x in Mar 2026.
Compare NBIX with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Neurocrine Biosciences Inc (NBIX) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Neurocrine Biosciences Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 2.9B with 28% growth year-over-year. Profit margins of 16.7% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 28% YoY, reaching 2.9B. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
ROE of 1640.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Neurocrine Biosciences Inc maintain 28%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Neurocrine Biosciences Inc.
Bottom Line
Neurocrine Biosciences Inc offers an attractive blend of growth (28% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Neurocrine Biosciences Inc(NBIX)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.